Combined Pd-1 Inhibition (Pembrolizumab) And Ccr5 Inhibition (Maraviroc) For The Treatment Of Refractory Microsatellite Stable (Mss) Metastatic Colorectal Cancer (Mcrc): First Results Of The Piccasso Phase I Trial.

Georg Martin Haag,Niels Halama,Christoph Springfeld,Barbara Grün,Leonidas Apostolidis,Stefanie Zschaebitz,Mareike Dietrich,Anne-Katrin Berger,Tim Frederik Weber,Inka Zoernig,Lisa Waberer,Daniel Wilhelm Mueller,Salah-Eddin Al-Batran,Dirk Jaeger

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 22|浏览41

暂无评分

摘要

3010Background: Checkpoint inhibition using PD-1/PD-L1 inhibitors does not show clinically relevant activity in MSS/pMMR (Mismatch Repair Proficient) colorectal cancer. Previous work showed that in...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要